Novaliq ’ s NovaTears dry eye disease therapy launches in New Zealand

Novaliq today launched its dry eye disease therapy, NovaTears, in New Zealand and said that it won registrational approval in Australia.
The Germany-based company inked an exclusive licensing partnership earlier this year with AFT Pharmaceuticals (ASX:AFP) to commercialize Novaliq’s water-free topical eye drops in Australia.
Get the full story at our sister site, Drug Delivery Business News.
The post Novaliq’s NovaTears dry eye disease therapy launches in New Zealand appeared first on MassDevice.

Source: Mass Device - October 30, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals AFT Pharmaceuticals Novaliq GmbH Source Type: news